Walgreen’s Renewed Growth Momentum Makes for a Great Stock Pick in 2014
Walgreen's recent focus on becoming a global pharmacy has started to pay off in a big way with impressive net income growth in the first quarter of fiscal 2014.
A Long Road Ahead for This Embattled Blood Thinner
The enormous rough diamond that Merck picked up in the Schering-Plough merger has been cut smaller and smaller during costly late stage development. Soon, investors will know if it has a chance of recouping its costs.
3 Pharmacy Businesses Keep Delivering Good Value to Investors
Walgreen, with its two long-term partnerships, can deliver good value to its shareholders. CVS and Express Scripts also benefit investors with their dividends and share buybacks.
Payor Trouble for Advair, GlaxoSmithKline Drugs in 2014
A number of well-known GlaxoSmithKline drugs, including one major blockbuster, will no longer be covered by the largest pharmacy benefit manager in the U.S. beginning Jan. 1.
Is Express Scripts’ Future Threatened by Private Health Exchanges?
Express Scripts and other large players in the drug distribution business are unlikely to lose much market share to private health exchanges when Obamacare comes into operation in 2014.
Why Obamacare Won't Stand in the Way of CVS Caremark in 2014
The recent partnership between CVS Caremark and Cardinal Health will help CVS to compete more effectively with larger rivals such as Walgreen and Express Scripts, and also help the company stay on top of the rapidly shifting drug distribution business.